These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33121965)

  • 41. The prognostic significance of proliferative indices in surgically resected IIIA-N2 non-small cell lung cancer after induction chemotherapy.
    Corzani R; Luzzi L; Spina D; Voltolini L; Paladini P; Ghiribelli C; Ghisalberti M; Borrelli R; Meniconi F; Monaci N; Gotti G
    J Cardiovasc Surg (Torino); 2017 Oct; 58(5):763-769. PubMed ID: 24740119
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Propensity score-matched analysis of adjuvant chemotherapy for stage I non-small cell lung cancer.
    Tsutani Y; Miyata Y; Kushitani K; Takeshima Y; Yoshimura M; Okada M
    J Thorac Cardiovasc Surg; 2014 Oct; 148(4):1179-85. PubMed ID: 25112928
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Defining the role of adjuvant therapy for early-stage large cell neuroendocrine carcinoma.
    Wakeam E; Adibfar A; Stokes S; Leighl NB; Giuliani ME; Varghese TK; Darling GE
    J Thorac Cardiovasc Surg; 2020 May; 159(5):2043-2054.e9. PubMed ID: 31759623
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pathologic nodal clearance and complete response following neoadjuvant chemoradiation for clinical N2 non-small cell lung cancer: Predictors and long-term outcomes.
    Haque W; Verma V; Butler EB; Teh BS
    Lung Cancer; 2019 Apr; 130():93-100. PubMed ID: 30885358
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA-IIIB) lung cancer.
    Takeda S; Maeda H; Okada T; Yamaguchi T; Nakagawa M; Yokota S; Sawabata N; Ohta M
    Eur J Cardiothorac Surg; 2006 Jul; 30(1):184-9. PubMed ID: 16730452
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society).
    Couñago F; Rodriguez de Dios N; Montemuiño S; Jové-Teixidó J; Martin M; Calvo-Crespo P; López-Mata M; Samper-Ots MP; López-Guerra JL; García-Cañibano T; Díaz-Díaz V; de Ingunza-Barón L; Murcia-Mejía M; Alcántara P; Corona J; Puertas MM; Chust M; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Thuissard IJ; Sanz-Rosa D; Taboada B
    Lung Cancer; 2018 Apr; 118():119-127. PubMed ID: 29571989
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term effects of neoadjuvant radiotherapy, adjuvant radiotherapy, and chemotherapy-only on survival of locally advanced non-small cell lung Cancer undergoing surgery: a propensity-matched analysis.
    Wang X; Yin C; Su S; Li X; Wang C; Zhang C; Liu M
    BMC Cancer; 2018 Nov; 18(1):1067. PubMed ID: 30400782
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adjuvant Management of Pathologic Node-Positive Disease After Definitive Surgery for Clinical T1-2 N0 Rectal Cancer.
    Polamraju P; Haque W; Verma V; Wiederhold L; Hatch S; Butler EB; Teh BS
    Clin Colorectal Cancer; 2018 Sep; 17(3):e519-e530. PubMed ID: 29753642
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adjuvant Chemotherapy After Lobectomy for T1-2N0 Non-Small Cell Lung Cancer: Are the Guidelines Supported?
    Speicher PJ; Gu L; Wang X; Hartwig MG; D'Amico TA; Berry MF
    J Natl Compr Canc Netw; 2015 Jun; 13(6):755-61. PubMed ID: 26085391
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.
    Shinde A; Horne ZD; Li R; Glaser S; Massarelli E; Koczywas M; Erhunmwunsee L; Reckamp KL; Weksler B; Salgia R; Beriwal S; Amini A
    Lung Cancer; 2019 Jul; 133():136-143. PubMed ID: 31200820
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).
    Tanaka F; Miyahara R; Ohtake Y; Yanagihara K; Fukuse T; Hitomi S; Wada H
    Eur J Cardiothorac Surg; 1998 Sep; 14(3):256-62; discussion 263-4. PubMed ID: 9761434
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
    Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
    Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Two patterns of mediastinal lymph node resection for non-small cell lung cancer of stage IIIA: survival analysis of 219 cases].
    Zhang GQ; Han F; Gao SL; A DL; Pang ZL
    Ai Zheng; 2007 May; 26(5):519-23. PubMed ID: 17672944
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA (N2) non-small cell lung cancer without increasing adverse effects.
    Zhao X; Su Y; You J; Gong L; Zhang Z; Wang M; Zhao Z; Zhang Z; Li X; Wang C
    Oncotarget; 2016 Sep; 7(38):62619-62626. PubMed ID: 27566586
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Concurrent Versus Sequential Chemoradiation Therapy in Completely Resected Pathologic N2 Non-Small Cell Lung Cancer: Propensity-Matched Analysis of the National Cancer Data Base.
    Moreno AC; Haque W; Verma V; Fang P; Lin SH
    Ann Surg Oncol; 2018 May; 25(5):1245-1253. PubMed ID: 29484562
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of pathologic node-positive disease following initial surgery for clinical T1-2 N0 esophageal cancer: patterns of care and outcomes from the national cancer data base.
    Haque W; Verma V; Bernicker E; Butler EB; Teh BS
    Acta Oncol; 2018 Jun; 57(6):782-789. PubMed ID: 29188742
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non-small cell lung cancer.
    Zhang P; Duan J; Bai H; Wang Z; Gao S; Tan F; Gao Y; Wang X; Wan R; Xu J; He X; Feng X; Yu R; Sun J; Zhao Z; Fei K; Li N; He J; Wang J
    Thorac Cancer; 2021 Jan; 12(1):30-39. PubMed ID: 33111432
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Five-Year Survival Among Stage IIIA Lung Cancer Patients Receiving Two Different Treatment Modalities.
    Bilfinger T; Keresztes R; Albano D; Nemesure B
    Med Sci Monit; 2016 Jul; 22():2589-94. PubMed ID: 27442604
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Favourable outcomes in patients with early-stage non-small-cell lung cancer operated on by video-assisted thoracoscopic surgery: a propensity score-matched analysis.
    Dziedzic R; Marjanski T; Binczyk F; Polanska J; Sawicka W; Rzyman W
    Eur J Cardiothorac Surg; 2018 Sep; 54(3):547-553. PubMed ID: 29547899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.